CN102448968A - C-met蛋白激酶的取代的吡唑抑制剂 - Google Patents

C-met蛋白激酶的取代的吡唑抑制剂 Download PDF

Info

Publication number
CN102448968A
CN102448968A CN2010800231025A CN201080023102A CN102448968A CN 102448968 A CN102448968 A CN 102448968A CN 2010800231025 A CN2010800231025 A CN 2010800231025A CN 201080023102 A CN201080023102 A CN 201080023102A CN 102448968 A CN102448968 A CN 102448968A
Authority
CN
China
Prior art keywords
compound
hydrogen
methyl
cancer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800231025A
Other languages
English (en)
Chinese (zh)
Inventor
李磐
N·瓦尔
S·龙金
Q·唐
D·劳费尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN102448968A publication Critical patent/CN102448968A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2010800231025A 2009-05-28 2010-05-27 C-met蛋白激酶的取代的吡唑抑制剂 Pending CN102448968A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18178409P 2009-05-28 2009-05-28
US61/181,784 2009-05-28
PCT/US2010/036309 WO2010138663A1 (en) 2009-05-28 2010-05-27 Substituted pyrazole inhibitors of c-met protein kinase

Publications (1)

Publication Number Publication Date
CN102448968A true CN102448968A (zh) 2012-05-09

Family

ID=42370912

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800231025A Pending CN102448968A (zh) 2009-05-28 2010-05-27 C-met蛋白激酶的取代的吡唑抑制剂

Country Status (8)

Country Link
US (3) US8269012B2 (enExample)
EP (1) EP2435444A1 (enExample)
JP (1) JP2012528185A (enExample)
CN (1) CN102448968A (enExample)
AU (1) AU2010254053A1 (enExample)
CA (1) CA2762186A1 (enExample)
MX (1) MX2011012522A (enExample)
WO (1) WO2010138663A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073491A (zh) * 2013-01-25 2013-05-01 桑迪亚医药技术（上海）有限责任公司 一种2-（5,7-二氟-6-喹啉基）乙酸/丙酸（酯）的合成方法
WO2017114249A1 (zh) * 2015-12-31 2017-07-06 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
CN109897054A (zh) * 2017-12-08 2019-06-18 中国药科大学 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2435443B1 (en) * 2009-05-28 2013-07-31 Vertex Pharmaceuticals Incorporated Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase
ES2712717T3 (es) * 2012-07-27 2019-05-14 Sato Pharma Compuesto de difluorometileno
GR1009565B (el) * 2016-07-14 2019-08-06 Galenica Α.Ε. Νεα παραγωγα 1,2,4-τριαζολο-[3,4-b]-1,3,4-θειαδιαζολιων

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1553899A (zh) * 2001-06-22 2004-12-08 ������������ʽ���� 抑制肝细胞生长因子受体自磷酸化的喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
CN101018780A (zh) * 2004-08-26 2007-08-15 辉瑞大药厂 作为蛋白激酶抑制剂的吡唑取代的氨基杂芳基化合物
WO2008144767A1 (en) * 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568666A (en) * 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
AU2009316756B2 (en) * 2008-11-19 2016-02-25 Vertex Pharmaceuticals Incorporated A triazolothiadiazole inhibitor of c-Met protein kinase
EP2435443B1 (en) * 2009-05-28 2013-07-31 Vertex Pharmaceuticals Incorporated Aminopyrazole triazolothiadiazole inhibitors of c-met protien kinase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1553899A (zh) * 2001-06-22 2004-12-08 ������������ʽ���� 抑制肝细胞生长因子受体自磷酸化的喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
WO2005070891A2 (en) * 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
CN101018780A (zh) * 2004-08-26 2007-08-15 辉瑞大药厂 作为蛋白激酶抑制剂的吡唑取代的氨基杂芳基化合物
WO2008144767A1 (en) * 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103073491A (zh) * 2013-01-25 2013-05-01 桑迪亚医药技术（上海）有限责任公司 一种2-（5,7-二氟-6-喹啉基）乙酸/丙酸（酯）的合成方法
WO2017114249A1 (zh) * 2015-12-31 2017-07-06 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
KR20180095093A (ko) * 2015-12-31 2018-08-24 베이징 피어 바이오테크놀로지 리미티드 라이어빌리티 컴페니 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도
KR102127218B1 (ko) * 2015-12-31 2020-06-29 베이징 피어 바이오테크놀로지 리미티드 라이어빌리티 컴페니 뇌 신경 교종 치료용 약물 제조에서의 화합물의 용도
US11400088B2 (en) * 2015-12-31 2022-08-02 Beijing Pearl Biotechnology Limited Liability Company Uses of compound in preparation of drugs for treating brain glioma
CN109897054A (zh) * 2017-12-08 2019-06-18 中国药科大学 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途
CN109897054B (zh) * 2017-12-08 2021-12-10 中国药科大学 三唑并噻二唑类c-Met激酶抑制剂的制备方法及其用途

Also Published As

Publication number Publication date
EP2435444A1 (en) 2012-04-04
US20130018072A1 (en) 2013-01-17
JP2012528185A (ja) 2012-11-12
US8269013B2 (en) 2012-09-18
US20110124684A1 (en) 2011-05-26
CA2762186A1 (en) 2010-12-02
MX2011012522A (es) 2012-02-08
US8269012B2 (en) 2012-09-18
AU2010254053A1 (en) 2011-12-01
WO2010138663A1 (en) 2010-12-02
US20100305155A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
CN102216309B (zh) C-met蛋白激酶的三唑并噻二唑抑制剂
US8269013B2 (en) Substituted pyrazole inhibitors of c-Met protein kinase
TWI491614B (zh) Ｃ－ｍｅｔ蛋白質激酶之胺基吡唑三唑并噻二唑抑制劑
US8263776B2 (en) Inhibitors of c-Met protein kinase
HK1169401A (en) Substituted pyrazole inhibitors of c-met protein kinase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1169401

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120509

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1169401

Country of ref document: HK